SciRhom Secures EUR 63 Million in Series A Funding to Advance Autoimmune Disease Therapies

SciRhom, a pioneering biotechnology company based in Martinsried, has successfully raised EUR 63 million in a Series A funding round. This significant investment will drive the development of its innovative iRhom2-targeted antibody therapies, designed to combat autoimmune diseases. The financing round was led by prominent investors, including Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners. Bayern Kapital also contributed, alongside existing backers such as High-Tech Gründerfonds (HTGF) and PhiFund Ventures.  

Founded in 2016, SciRhom is committed to developing cutting-edge antibody treatments that inhibit key pro-inflammatory pathways. By targeting these signaling mechanisms, the company aims to create therapies that address not only autoimmune disorders but potentially other severe medical conditions.  

Our firm, Michalski - Hüttermann & Partner, is proud to have played an integral role in supporting SciRhom’s innovation journey. From the very beginning, we collaborated closely with the founders to design a comprehensive and multi-faceted patent strategy tailored to the biotech sector’s unique challenges.  

Given the complexity of antibody-based therapies and the varying patent requirements across jurisdictions, we ensured SciRhom’s intellectual property strategy was robust and future-proof. This included:  

• Identifying and protecting novel therapeutic targets  
• Developing layered patent protection to address different stages of product development  
• Optimizing the lifecycle management of key inventions  
• Balancing cost efficiency while maximizing the scope of protection  

Through strategic counselling and meticulous portfolio management, we helped secure SciRhom’s innovations, safeguarding the value they have created since their founding. This approach positions them well as they move forward with clinical development and global expansion.  

With the successful Series A funding now secured, SciRhom is poised to make a meaningful impact in the field of autoimmune therapies, and we are proud to support their mission.